Background/aim: Targeted intraoperative radiotherapy (TARGIT IORT) is an option during breast-conserving surgery (BCS). No data have yet been published regarding the safety of TARGIT IORT with implants in situ. TARGIT IORT is an attractive option in this context because of the risk of capsular fibrosis following external beam radiotherapy (EBRT) in such patients.
Patients And Methods: We are reporting a retrospective analysis of 16 patients who received TARGIT IORT during BCS for early breast cancer after previous implant-based breast augmentation. TARGIT IORT was performed using the Intrabeam™method.
Results: Follow-up varied from 98 to 5 months. There were no procedure-related complications. One patient developed local recurrence after 36 months of follow-up. Among the remaining patients (15/16), no breast-cancer-related events occurred.
Conclusion: This series of patients with TARGIT IORT during BCS after implant-based breast augmentation revealed no safety concerns and gives some confidence in discussing this option with selected patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.13582 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real world clinical outcomes from targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer: data from a large cohort at a national cancer institute.
Front Oncol
October 2024
Division of Surgery and Interventional Science, University College London, London, United Kingdom.
Introduction: Randomised evidence supports the use of partial breast irradiation (PBI) with targeted intraoperative radiotherapy (TARGIT-IORT) for early stage breast cancer, but prospective data from real-world adoption of this technique is also important. The aim of this study was to determine if the outcome reported in TARGIT-A trial could be replicated in large cohort of early stage breast cancer treated with TARGIT-IORT.
Methods: This prospective observational study analysed all patients treated with TARGIT-IORT between 2004 and 2021 in a single national cancer institute.
Case report: IORT as an alternative treatment option for breast cancer patients with difficulty staying still.
Front Oncol
September 2024
Breast Surgery Division, Department of Surgery, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, United States.
Article Synopsis
- Administering radiation therapy, particularly whole breast irradiation (WBI), is challenging for individuals with intellectual disabilities (ID) and psychiatric disorders due to difficulties in staying still; intraoperative radiotherapy (TARGIT-IORT) offers an alternative treatment.
- A case series involving four breast cancer patients showed that TARGIT-IORT was successfully administered to two patients with ID and two with psychiatric conditions, all of whom tolerated the procedure well and showed no evidence of disease in follow-up.
- The study highlights TARGIT-IORT as a promising treatment for breast cancer patients with ID and psychiatric disorders, suggesting it may address complications related to movement disorders and compliance, while noting the need for further research on its effectiveness in patients with difficulty
Qualitative exploration of patients' experiences with Intrabeam TARGeted Intraoperative radioTherapy (TARGIT-IORT) and External-Beam RadioTherapy Treatment (EBRT) for breast cancer.
BMJ Open
August 2024
Division of Surgery and Interventional Science, University College London, London, UK.
Objective: To gather a deep qualitative understanding of the perceived benefits and impacts of External-Beam RadioTherapy (EBRT) and TARGeted Intraoperative radioTherapy (TARGIT-IORT) using Intrabeam to assess how the treatments affected patient/care partner experiences during their cancer treatment and beyond.
Design And Participants: A patient-led working group was established to guide study design and to help validate findings. Patients with experience of receiving EBRT or TARGIT-IORT were purposively sampled by Hampshire Hospitals NHS Foundation Trust.
Acute and Long-Term Toxicity after Planned Intraoperative Boost and Whole Breast Irradiation in High-Risk Patients with Breast Cancer-Results from the Targeted Intraoperative Radiotherapy Boost Quality Registry (TARGIT BQR).
Cancers (Basel)
May 2024
Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Article Synopsis
- This study investigates using intraoperative radiotherapy (IORT) as an additional boost for high-risk breast cancer patients, combined with standard external beam radiotherapy (EBRT), and aims to evaluate treatment outcomes and side effects.
- The study, known as TARGIT BQR, included 1133 patients across 10 centers from 2011 to 2020, assessing both acute and long-term toxicity following the IORT boost delivered immediately after tumor removal.
- Findings showed that the IORT boost is feasible and generally safe, with low rates of serious side effects; however, some patients experienced mild to moderate acute and chronic effects such as erythema and fibrosis.
Intraoperative radiation therapy with 50 kV x-rays: A multi-institutional review.
J Appl Clin Med Phys
March 2024
Department of Radiation Oncology, Summit Medical Center, Emeryville, California, USA.
Article Synopsis
- The report discusses the implementation of a low kV intraoperative radiation therapy (IORT) program using the INTRABEAM® System, focusing on best practices for quality assurance and clinical workflow based on experiences from eight institutions.
- It emphasizes the importance of routine quality assurance procedures and detailed dosimetry measurements, including safety checks and calibration protocols to ensure accurate dose delivery during IORT.
- The report also suggests areas for future research, such as improving treatment planning techniques and enhancing prescribed dose accuracy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!